酮内酯类药物HMR 3647对近期革兰氏阳性临床分离株和流感嗜血杆菌的体外活性。
In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae.
作者信息
Barry A L, Fuchs P C, Brown S D
机构信息
The Clinical Microbiology Institute, Wilsonville, Oregon 97070, USA.
出版信息
Antimicrob Agents Chemother. 1998 Aug;42(8):2138-40. doi: 10.1128/AAC.42.8.2138.
Abstract
The ketolide HMR 3647 (previously RU 66647) was evaluated against 2, 563 recent clinical isolates of gram-positive pathogens and 200 Haemophilus influenzae isolates. HMR 3647 was active against macrolide-resistant streptococci, including pneumococci, but was not active against macrolide- or lincosamide-resistant staphylococci. Against H. influenzae, the potency of HMR 3647 was similar to that of azithromycin.
摘要
对酮内酯类药物HMR 3647（以前称为RU 66647）针对2563株近期临床分离的革兰氏阳性病原体和200株流感嗜血杆菌分离株进行了评估。HMR 3647对大环内酯类耐药链球菌，包括肺炎球菌有活性，但对大环内酯类或林可酰胺类耐药葡萄球菌无活性。对于流感嗜血杆菌，HMR 3647的效力与阿奇霉素相似。
相似文献
1
In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae.
Antimicrob Agents Chemother. 1998 Aug;42(8):2138-40. doi: 10.1128/AAC.42.8.2138.
2
In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.
Eur J Clin Microbiol Infect Dis. 1997 Oct;16(10):767-9. doi: 10.1007/BF01709263.
3
In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.
Antimicrob Agents Chemother. 1997 Feb;41(2):454-9. doi: 10.1128/AAC.41.2.454.
4
Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains.
Diagn Microbiol Infect Dis. 1998 Jun;31(2):349-53. doi: 10.1016/s0732-8893(98)00022-4.
5
Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens.
Bioorg Med Chem Lett. 1999 Nov 1;9(21):3075-80. doi: 10.1016/s0960-894x(99)00534-x.
6
Antimicrobial activity of RU-66647, a new ketolide.
Diagn Microbiol Infect Dis. 1997 Jan-Feb;27(1-2):7-12. doi: 10.1016/s0732-8893(96)00181-2.
7
In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.
Antimicrob Agents Chemother. 1997 May;41(5):1196-202. doi: 10.1128/AAC.41.5.1196.
8
In-vitro activity of the new ketolide antibiotic HMR 3647 against gram-positive bacteria.
J Antimicrob Chemother. 1998 Sep;42(3):297-301. doi: 10.1093/jac/42.3.297.
9
In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci.
J Antimicrob Chemother. 1999 Oct;44(4):445-53. doi: 10.1093/jac/44.4.445.
10
In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria.
Antimicrob Agents Chemother. 1999 Apr;43(4):930-6. doi: 10.1128/AAC.43.4.930.
引用本文的文献
1
Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia.
Ther Clin Risk Manag. 2006 Mar;2(1):59-75.
2
Antibiotics for treatment of resistant gram-positive coccal infections.
Indian J Pediatr. 2006 Apr;73(4):323-34. doi: 10.1007/BF02825827.
3
Recovery of interfering bacteria in the nasopharynx following antimicrobial therapy of acute maxillary sinusitis with telithromycin or amoxicillin-clavulanate.
Antimicrob Agents Chemother. 2005 Nov;49(11):4793-4. doi: 10.1128/AAC.49.11.4793-4794.2005.
4
Telithromycin.
Drugs. 2004;64(15):1683-94; discussion 1695-6. doi: 10.2165/00003495-200464150-00006.
5
The ketolides: a critical review.
Drugs. 2002;62(12):1771-804. doi: 10.2165/00003495-200262120-00006.
6
Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers.
Antimicrob Agents Chemother. 2002 Mar;46(3):917-21. doi: 10.1128/AAC.46.3.917-921.2002.
7
Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci.
Antimicrob Agents Chemother. 2002 Mar;46(3):783-6. doi: 10.1128/AAC.46.3.783-786.2002.
8
In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.
Antimicrob Agents Chemother. 2001 Nov;45(11):3250-2. doi: 10.1128/AAC.45.11.3250-3252.2001.
9
In vitro activity of the ketolide ABT-773.
Antimicrob Agents Chemother. 2001 Oct;45(10):2922-4. doi: 10.1128/AAC.45.10.2922-2924.2001.
10
Telithromycin.
Drugs. 2001;61(6):815-29; discussion 830-1. doi: 10.2165/00003495-200161060-00016.
本文引用的文献
1
Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).
Antimicrob Agents Chemother. 1998 Apr;42(4):945-6. doi: 10.1128/AAC.42.4.945.
2
In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.
Eur J Clin Microbiol Infect Dis. 1997 Oct;16(10):767-9. doi: 10.1007/BF01709263.
3
Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens.
Antimicrob Agents Chemother. 1997 Oct;41(10):2149-58. doi: 10.1128/AAC.41.10.2149.
4
Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004).
Antimicrob Agents Chemother. 1997 Sep;41(9):2019-22. doi: 10.1128/AAC.41.9.2019.
5
Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA.
J Antimicrob Chemother. 1997 Jul;40(1):139-40. doi: 10.1093/jac/40.1.139.
6
In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.
Antimicrob Agents Chemother. 1997 May;41(5):1196-202. doi: 10.1128/AAC.41.5.1196.
7
Antimicrobial activity of RU-66647, a new ketolide.
Diagn Microbiol Infect Dis. 1997 Jan-Feb;27(1-2):7-12. doi: 10.1016/s0732-8893(96)00181-2.
8
In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.
Antimicrob Agents Chemother. 1997 Feb;41(2):454-9. doi: 10.1128/AAC.41.2.454.
Zotero 插件